Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-04

AUTHORS

Brigitte Dréno, Robert Bissonnette, Angélique Gagné-Henley, Benjamin Barankin, Charles Lynde, Nabil Kerrouche, Jerry Tan

ABSTRACT

BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne. METHODS: In this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; ≥ 25 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety. RESULTS: Included subjects (n = 67) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was - 15.5% for A0.3/BPO2.5 versus + 14.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p < 0.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p < 0.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p < 0.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p < 0.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively). CONCLUSIONS: Topical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+ 14.4%) but decreased with A0.3/BPO2.5 (- 15.5%) over 24 weeks. TRIAL REGISTRY: ClinicalTrials.gov identifier NCT02735421. More... »

PAGES

275-286

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40257-018-0352-y

DOI

http://dx.doi.org/10.1007/s40257-018-0352-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101557886

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29549588


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acne Vulgaris", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adapalene", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Cutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrophy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoyl Peroxide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cicatrix", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dermatologic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Face", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gels", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Nantes", 
          "id": "https://www.grid.ac/institutes/grid.277151.7", 
          "name": [
            "Department of Dermato-Cancerology, CIC 1413, CRCINA Inserm 1232, CHU Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dr\u00e9no", 
        "givenName": "Brigitte", 
        "id": "sg:person.01146563400.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146563400.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Innovaderm (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.477377.7", 
          "name": [
            "Innovaderm Research, Montreal, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bissonnette", 
        "givenName": "Robert", 
        "id": "sg:person.01324371727.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324371727.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Dre Ang\u00e9lique Gagn\u00e9-Henley MD Inc, St-J\u00e9r\u00f4me, Qu\u00e9bec, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gagn\u00e9-Henley", 
        "givenName": "Ang\u00e9lique", 
        "id": "sg:person.01304742261.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304742261.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Toronto Research Centre Inc, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barankin", 
        "givenName": "Benjamin", 
        "id": "sg:person.01171242514.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171242514.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Lynde Institute for Dermatology, Markham, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lynde", 
        "givenName": "Charles", 
        "id": "sg:person.0651157151.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651157151.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Galderma R&D, Sophia Antipolis, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kerrouche", 
        "givenName": "Nabil", 
        "id": "sg:person.0711702007.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711702007.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Windsor Clinical Research", 
          "id": "https://www.grid.ac/institutes/grid.478093.1", 
          "name": [
            "University of Western Ontario, London, Ontario, Canada", 
            "Windsor Clinical Research Inc, Windsor, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Jerry", 
        "id": "sg:person.01161577034.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161577034.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0002-9440(10)62479-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004674372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jid.5700213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005100408", 
          "https://doi.org/10.1038/sj.jid.5700213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd011946.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009212741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2004.10.879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020161160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1034/j.1600-0625.12.s2.6.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021229833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-016-0159-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021900708", 
          "https://doi.org/10.1007/s13555-016-0159-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-016-0159-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021900708", 
          "https://doi.org/10.1007/s13555-016-0159-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.13675", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022564177"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2230.1994.tb01200.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023208605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40257-016-0178-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025156324", 
          "https://doi.org/10.1007/s40257-016-0178-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40257-016-0178-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025156324", 
          "https://doi.org/10.1007/s40257-016-0178-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1468-3083.2007.02190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035384879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1067/mjd.2003.618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036029799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1067/mjd.2003.618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036029799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000246015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038087431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0190-9622(98)70446-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039631411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2133.2001.04276.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044540825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-4632.2011.05029.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045132990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199308193290803", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045679286"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.14026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051655913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1099/ijsem.0.001367", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060389385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077123508", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/central/cn-00530929", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077123508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077665496", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079192754", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1084503136", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.14379", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085755199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-017-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085864872", 
          "https://doi.org/10.1007/s13555-017-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-017-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085864872", 
          "https://doi.org/10.1007/s13555-017-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1090396782", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-017-0203-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092188982", 
          "https://doi.org/10.1007/s13555-017-0203-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2017.09.078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092595105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-018-0231-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101555723", 
          "https://doi.org/10.1007/s13555-018-0231-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13555-018-0231-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101555723", 
          "https://doi.org/10.1007/s13555-018-0231-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04", 
    "datePublishedReg": "2018-04-01", 
    "description": "BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring.\nOBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne.\nMETHODS: In this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; \u2265\u200925 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety.\nRESULTS: Included subjects (n\u2009=\u200967) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was -\u200915.5% for A0.3/BPO2.5 versus \u2009+\u00a014.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p\u2009<\u20090.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p\u2009<\u20090.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p\u2009<\u20090.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p\u2009<\u20090.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively).\nCONCLUSIONS: Topical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+\u200914.4%) but decreased with A0.3/BPO2.5 (-\u200915.5%) over 24\u00a0weeks.\nTRIAL REGISTRY: ClinicalTrials.gov identifier NCT02735421.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40257-018-0352-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1021743", 
        "issn": [
          "1175-0561", 
          "1179-1888"
        ], 
        "name": "American Journal of Clinical Dermatology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison", 
    "pagination": "275-286", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f829e67c4af6fc400ce3010f2e27e176987d2832756c88cfc1966759dbcbb26d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29549588"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100895290"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40257-018-0352-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101557886"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40257-018-0352-y", 
      "https://app.dimensions.ai/details/publication/pub.1101557886"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29191_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40257-018-0352-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0352-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0352-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0352-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40257-018-0352-y'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      78 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40257-018-0352-y schema:about N08e8d6438f2f41bc86fe3efd4ff11849
2 N0c6ef2cec45e46409aa6acdaaf926129
3 N12ddb9d0790247cb8838bd51a7179146
4 N13d3b9ef897f4c93bb6d696849aeefe2
5 N13df8024fb064d23a0cbaff53779729f
6 N17ad05c0fffb48f0aecd2d09949b52b6
7 N304bca932fdd442ea8d99cabd50a0d94
8 N352d81e7aac746b28ea8ac71dec0d0d3
9 N36b54a5e9b3a445a8434011f8382d533
10 N4a732cac39804739ae92537893c8c4d6
11 N4b7c3db84b87424a8bc5e7f5965208c2
12 N4cdad1e2e08a4872bef02b952e3871be
13 N5b2f65a300c4456891c250e0f490873a
14 N762ce70e09774cc7a862ef7855535632
15 Na0250e8b39d24f9492611689ece96041
16 Naafb38c212af45d0942eadb6472942a0
17 Nc686c3221ca942028a6283f0e226147d
18 Ne1a85a6fc9d24dfbb3fdfc652ba671d2
19 Nf547bbfea3a34101bc12dca0cc4e6a75
20 Nffe2878edd964bf0b40f7a2a49bddc18
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N3420fffdeb1d41e28ed20276eb80e7a2
24 schema:citation sg:pub.10.1007/s13555-016-0159-9
25 sg:pub.10.1007/s13555-017-0185-2
26 sg:pub.10.1007/s13555-017-0203-4
27 sg:pub.10.1007/s13555-018-0231-8
28 sg:pub.10.1007/s40257-016-0178-4
29 sg:pub.10.1038/sj.jid.5700213
30 https://app.dimensions.ai/details/publication/pub.1077123508
31 https://app.dimensions.ai/details/publication/pub.1077665496
32 https://app.dimensions.ai/details/publication/pub.1079192754
33 https://app.dimensions.ai/details/publication/pub.1084503136
34 https://app.dimensions.ai/details/publication/pub.1090396782
35 https://doi.org/10.1002/14651858.cd011946.pub2
36 https://doi.org/10.1002/central/cn-00530929
37 https://doi.org/10.1016/j.jaad.2004.10.879
38 https://doi.org/10.1016/j.jaad.2017.09.078
39 https://doi.org/10.1016/s0002-9440(10)62479-0
40 https://doi.org/10.1016/s0190-9622(98)70446-3
41 https://doi.org/10.1034/j.1600-0625.12.s2.6.x
42 https://doi.org/10.1046/j.1365-2133.2001.04276.x
43 https://doi.org/10.1056/nejm199308193290803
44 https://doi.org/10.1067/mjd.2003.618
45 https://doi.org/10.1099/ijsem.0.001367
46 https://doi.org/10.1111/j.1365-2230.1994.tb01200.x
47 https://doi.org/10.1111/j.1365-4632.2011.05029.x
48 https://doi.org/10.1111/j.1468-3083.2007.02190.x
49 https://doi.org/10.1111/jdv.13675
50 https://doi.org/10.1111/jdv.14026
51 https://doi.org/10.1111/jdv.14379
52 https://doi.org/10.1159/000246015
53 schema:datePublished 2018-04
54 schema:datePublishedReg 2018-04-01
55 schema:description BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne. METHODS: In this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; ≥ 25 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety. RESULTS: Included subjects (n = 67) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was - 15.5% for A0.3/BPO2.5 versus  + 14.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p < 0.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p < 0.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p < 0.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p < 0.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively). CONCLUSIONS: Topical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+ 14.4%) but decreased with A0.3/BPO2.5 (- 15.5%) over 24 weeks. TRIAL REGISTRY: ClinicalTrials.gov identifier NCT02735421.
56 schema:genre research_article
57 schema:inLanguage en
58 schema:isAccessibleForFree true
59 schema:isPartOf N6feaeebdaff34bd086c86f35a60f8b45
60 Ne649a2751d394e508afc640776594ca0
61 sg:journal.1021743
62 schema:name Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison
63 schema:pagination 275-286
64 schema:productId N60c6c7bfdac449b79c605c4552475b73
65 N82d2c20d29104b5d92cce1ea6064eeda
66 N97597f24755e4060839e3e5f0bc878dc
67 Nbde475cb276348029a12fa637f04a954
68 Nc1d41860d0fb41289399b5fea6ee429c
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101557886
70 https://doi.org/10.1007/s40257-018-0352-y
71 schema:sdDatePublished 2019-04-11T11:52
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher Na2be30b70a0540ecb37709cea20fb043
74 schema:url https://link.springer.com/10.1007%2Fs40257-018-0352-y
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N08e8d6438f2f41bc86fe3efd4ff11849 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Humans
80 rdf:type schema:DefinedTerm
81 N0c6ef2cec45e46409aa6acdaaf926129 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adapalene
83 rdf:type schema:DefinedTerm
84 N12ddb9d0790247cb8838bd51a7179146 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Treatment Outcome
86 rdf:type schema:DefinedTerm
87 N13d3b9ef897f4c93bb6d696849aeefe2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Female
89 rdf:type schema:DefinedTerm
90 N13df8024fb064d23a0cbaff53779729f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Face
92 rdf:type schema:DefinedTerm
93 N17ad05c0fffb48f0aecd2d09949b52b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Administration, Cutaneous
95 rdf:type schema:DefinedTerm
96 N1ee7f34cab1e413e9b30aa7783f76005 rdf:first sg:person.01304742261.52
97 rdf:rest N63ae0a36b5894a35a5ded0dad44cf7a5
98 N304bca932fdd442ea8d99cabd50a0d94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Male
100 rdf:type schema:DefinedTerm
101 N3420fffdeb1d41e28ed20276eb80e7a2 rdf:first sg:person.01146563400.12
102 rdf:rest N8d1c429296fe430eb3f6a5bfbd4d6c03
103 N352d81e7aac746b28ea8ac71dec0d0d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Acne Vulgaris
105 rdf:type schema:DefinedTerm
106 N36b54a5e9b3a445a8434011f8382d533 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Cicatrix
108 rdf:type schema:DefinedTerm
109 N4a732cac39804739ae92537893c8c4d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Double-Blind Method
111 rdf:type schema:DefinedTerm
112 N4b7c3db84b87424a8bc5e7f5965208c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Adult
114 rdf:type schema:DefinedTerm
115 N4cdad1e2e08a4872bef02b952e3871be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Dermatologic Agents
117 rdf:type schema:DefinedTerm
118 N53805d71f13544919be899fa8c9fc2e0 schema:name Dre Angélique Gagné-Henley MD Inc, St-Jérôme, Québec, Canada
119 rdf:type schema:Organization
120 N5b2f65a300c4456891c250e0f490873a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Young Adult
122 rdf:type schema:DefinedTerm
123 N5fe090f1d6084dd8ab0997604582702e rdf:first sg:person.0711702007.10
124 rdf:rest Nee514715a2af4bf4b397a8cc9de047d8
125 N60c6c7bfdac449b79c605c4552475b73 schema:name pubmed_id
126 schema:value 29549588
127 rdf:type schema:PropertyValue
128 N63ae0a36b5894a35a5ded0dad44cf7a5 rdf:first sg:person.01171242514.54
129 rdf:rest Ndd8844ca79734e3888b1a599feb80e66
130 N6feaeebdaff34bd086c86f35a60f8b45 schema:issueNumber 2
131 rdf:type schema:PublicationIssue
132 N762ce70e09774cc7a862ef7855535632 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Skin
134 rdf:type schema:DefinedTerm
135 N7d45ca174b7a4889a48979e310072e7d schema:name Galderma R&D, Sophia Antipolis, France
136 rdf:type schema:Organization
137 N82d2c20d29104b5d92cce1ea6064eeda schema:name nlm_unique_id
138 schema:value 100895290
139 rdf:type schema:PropertyValue
140 N86a5564c5ddd4e0abfc8ef41866529a2 schema:name Toronto Research Centre Inc, Toronto, Ontario, Canada
141 rdf:type schema:Organization
142 N8d1c429296fe430eb3f6a5bfbd4d6c03 rdf:first sg:person.01324371727.48
143 rdf:rest N1ee7f34cab1e413e9b30aa7783f76005
144 N97597f24755e4060839e3e5f0bc878dc schema:name dimensions_id
145 schema:value pub.1101557886
146 rdf:type schema:PropertyValue
147 Na0250e8b39d24f9492611689ece96041 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Benzoyl Peroxide
149 rdf:type schema:DefinedTerm
150 Na2be30b70a0540ecb37709cea20fb043 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 Naafb38c212af45d0942eadb6472942a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Adolescent
154 rdf:type schema:DefinedTerm
155 Nbde475cb276348029a12fa637f04a954 schema:name doi
156 schema:value 10.1007/s40257-018-0352-y
157 rdf:type schema:PropertyValue
158 Nc1d41860d0fb41289399b5fea6ee429c schema:name readcube_id
159 schema:value f829e67c4af6fc400ce3010f2e27e176987d2832756c88cfc1966759dbcbb26d
160 rdf:type schema:PropertyValue
161 Nc686c3221ca942028a6283f0e226147d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Severity of Illness Index
163 rdf:type schema:DefinedTerm
164 Ndd8844ca79734e3888b1a599feb80e66 rdf:first sg:person.0651157151.28
165 rdf:rest N5fe090f1d6084dd8ab0997604582702e
166 Ne1a85a6fc9d24dfbb3fdfc652ba671d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Drug Combinations
168 rdf:type schema:DefinedTerm
169 Ne649a2751d394e508afc640776594ca0 schema:volumeNumber 19
170 rdf:type schema:PublicationVolume
171 Nee514715a2af4bf4b397a8cc9de047d8 rdf:first sg:person.01161577034.34
172 rdf:rest rdf:nil
173 Nf547bbfea3a34101bc12dca0cc4e6a75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Atrophy
175 rdf:type schema:DefinedTerm
176 Nf9efaa93d3104766a69530f39e302213 schema:name Lynde Institute for Dermatology, Markham, Ontario, Canada
177 rdf:type schema:Organization
178 Nffe2878edd964bf0b40f7a2a49bddc18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Gels
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:journal.1021743 schema:issn 1175-0561
188 1179-1888
189 schema:name American Journal of Clinical Dermatology
190 rdf:type schema:Periodical
191 sg:person.01146563400.12 schema:affiliation https://www.grid.ac/institutes/grid.277151.7
192 schema:familyName Dréno
193 schema:givenName Brigitte
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146563400.12
195 rdf:type schema:Person
196 sg:person.01161577034.34 schema:affiliation https://www.grid.ac/institutes/grid.478093.1
197 schema:familyName Tan
198 schema:givenName Jerry
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161577034.34
200 rdf:type schema:Person
201 sg:person.01171242514.54 schema:affiliation N86a5564c5ddd4e0abfc8ef41866529a2
202 schema:familyName Barankin
203 schema:givenName Benjamin
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171242514.54
205 rdf:type schema:Person
206 sg:person.01304742261.52 schema:affiliation N53805d71f13544919be899fa8c9fc2e0
207 schema:familyName Gagné-Henley
208 schema:givenName Angélique
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304742261.52
210 rdf:type schema:Person
211 sg:person.01324371727.48 schema:affiliation https://www.grid.ac/institutes/grid.477377.7
212 schema:familyName Bissonnette
213 schema:givenName Robert
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324371727.48
215 rdf:type schema:Person
216 sg:person.0651157151.28 schema:affiliation Nf9efaa93d3104766a69530f39e302213
217 schema:familyName Lynde
218 schema:givenName Charles
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651157151.28
220 rdf:type schema:Person
221 sg:person.0711702007.10 schema:affiliation N7d45ca174b7a4889a48979e310072e7d
222 schema:familyName Kerrouche
223 schema:givenName Nabil
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711702007.10
225 rdf:type schema:Person
226 sg:pub.10.1007/s13555-016-0159-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021900708
227 https://doi.org/10.1007/s13555-016-0159-9
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s13555-017-0185-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085864872
230 https://doi.org/10.1007/s13555-017-0185-2
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s13555-017-0203-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092188982
233 https://doi.org/10.1007/s13555-017-0203-4
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s13555-018-0231-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101555723
236 https://doi.org/10.1007/s13555-018-0231-8
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s40257-016-0178-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025156324
239 https://doi.org/10.1007/s40257-016-0178-4
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/sj.jid.5700213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005100408
242 https://doi.org/10.1038/sj.jid.5700213
243 rdf:type schema:CreativeWork
244 https://app.dimensions.ai/details/publication/pub.1077123508 schema:CreativeWork
245 https://app.dimensions.ai/details/publication/pub.1077665496 schema:CreativeWork
246 https://app.dimensions.ai/details/publication/pub.1079192754 schema:CreativeWork
247 https://app.dimensions.ai/details/publication/pub.1084503136 schema:CreativeWork
248 https://app.dimensions.ai/details/publication/pub.1090396782 schema:CreativeWork
249 https://doi.org/10.1002/14651858.cd011946.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009212741
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1002/central/cn-00530929 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077123508
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/j.jaad.2004.10.879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020161160
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/j.jaad.2017.09.078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092595105
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/s0002-9440(10)62479-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004674372
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/s0190-9622(98)70446-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039631411
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1034/j.1600-0625.12.s2.6.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021229833
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1046/j.1365-2133.2001.04276.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1044540825
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1056/nejm199308193290803 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045679286
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1067/mjd.2003.618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036029799
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1099/ijsem.0.001367 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060389385
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1111/j.1365-2230.1994.tb01200.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023208605
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1111/j.1365-4632.2011.05029.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045132990
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1111/j.1468-3083.2007.02190.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035384879
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1111/jdv.13675 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022564177
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1111/jdv.14026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051655913
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1111/jdv.14379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085755199
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1159/000246015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038087431
284 rdf:type schema:CreativeWork
285 https://www.grid.ac/institutes/grid.277151.7 schema:alternateName Centre Hospitalier Universitaire de Nantes
286 schema:name Department of Dermato-Cancerology, CIC 1413, CRCINA Inserm 1232, CHU Nantes, Nantes, France
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.477377.7 schema:alternateName Innovaderm (Canada)
289 schema:name Innovaderm Research, Montreal, Canada
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.478093.1 schema:alternateName Windsor Clinical Research
292 schema:name University of Western Ontario, London, Ontario, Canada
293 Windsor Clinical Research Inc, Windsor, Ontario, Canada
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...